PERSIRIS study: observational study, postmarketing, prospective, to evaluate the persistence to treatment with monthly risedronate in women with osteoporosis

• Published in: Atención primaria 2016-05, Vol.48 (5), p.316-324
• Main Authors: Sitjar Martínez de Sas, Salvador, Aguilera de la Fuente, María Teresa, Combalía Romera, Josep, Menacho Pascual, Ignacio, González Martínez, Susana, Altés Boronat, Andreu
• Format: Article
• Language: Spanish
• Subjects: Aged; Bone Density Conservation Agents - administration & dosage; Female; Humans; Medication Adherence - statistics & numerical data; Osteoporosis - drug therapy; Product Surveillance, Postmarketing; Prospective Studies; Risedronate Sodium - administration & dosage; Time Factors
• ISSN: 1578-1275
• DOI: 10.1016/j.aprim.2015.04.011

To assess the persistence of treatment with monthly risedronate and know the reasons of persistence and nontherapeutic persistence and the profile of the non-persistent patients. Observational, postmarketin and prospective study. Primary care, traumatology, rheumatology, gynecology and geriatrics of Catalonia. Women with osteoporosis treated with monthly risedronate that previously had abandoned weekly bisphosphonate therapy. Percentage of patients on persistent monthly risedronate year of their prescription, reasons for persistent and non persistent and profile of non persistent patients in relation to biodemographic data, clinical data and risk factors for fracture. 289 evaluable patients with a mean age of 68.3. At 12 months of initiation with monthly risedronate, 58.1% of patients remained on treatment. Most frequent reasons for leaving: fear of having side effects and belief that the disease is typical of the age. Reasons remarkable persistence: comfort/ease and dosage. Significant differences were observed between persistent and non-persistent patients relative to: employment status, number of concomitant therapy and height; however the results of possible associated factors must be contextualized within the study characteristics and the difference in size does not seem clinically relevant. The administration of therapeutic patterns more comfortable as monthly risedronate in osteoporosis, could facilitate persistence in patients improving the effectiveness of the drug. However in that persistence can also influence biodemographic and clinical variables and diverse of various kinds.